Literature DB >> 9373258

Methylation of the Epstein-Barr virus genome in normal lymphocytes.

K D Robertson1, R F Ambinder.   

Abstract

Epstein-Barr virus (EBV) latent infection in B cells persists over years or decades despite a sustained cytotoxic immune response to viral antigens. We present data that methylated EBV DNA can be detected in the normal lymphocytes of healthy volunteers. Whereas methylation of foreign DNA has been recognized as a potential cellular defense mechanism, methylation of EBV DNA may be an essential part of the virus life cycle in vivo, explaining the persistence of virus-infected B cells in the face of immune surveillance. Methylation of the C promoter helps to prevent expression of the immunodominant antigens expressed from this promoter. First recognized in tumors, methylation-associated evasion of immune surveillance is not an aberration restricted to tumor tissue but is detected in normal EBV-infected lymphocytes. Methylation of the viral genome in latency also provides an explanation for the CpG suppression associated with EBV but not other large DNA viruses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9373258

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis.

Authors:  Q Tao; L J Swinnen; J Yang; G Srivastava; K D Robertson; R F Ambinder
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity.

Authors:  H Chen; J M Lee; Y Wang; D P Huang; R F Ambinder; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

3.  Contributions of CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency.

Authors:  David J Hughes; Elessa M Marendy; Carol A Dickerson; Kristen D Yetming; Clare E Sample; Jeffery T Sample
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

4.  An auto-regulatory loop for EBV LMP2A involves activation of Notch.

Authors:  Leah J Anderson; Richard Longnecker
Journal:  Virology       Date:  2007-11-05       Impact factor: 3.616

5.  Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing.

Authors:  Mikio Yoshioka; Michelle M Crum; Jeffery T Sample
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

6.  Epstein-Barr virus transcription activator R upregulates BARF1 expression by direct binding to its promoter, independent of methylation.

Authors:  E K Hoebe; C Wille; E S Hopmans; A R Robinson; J M Middeldorp; S C Kenney; A E Greijer
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

7.  The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive.

Authors:  Q Tao; K D Robertson; A Manns; A Hildesheim; R F Ambinder
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

8.  trans-Repression of protein expression dependent on the Epstein-Barr virus promoter Wp during latency.

Authors:  David J Hughes; Carol A Dickerson; Marie S Shaner; Clare E Sample; Jeffery T Sample
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

Review 9.  Epigenetic regulation of EBV persistence and oncogenesis.

Authors:  Italo Tempera; Paul M Lieberman
Journal:  Semin Cancer Biol       Date:  2014-01-24       Impact factor: 15.707

10.  A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.

Authors:  Jianqing Lin; Jill Gilbert; Michelle A Rudek; James A Zwiebel; Steve Gore; Anchalee Jiemjit; Ming Zhao; Sharyn D Baker; Richard F Ambinder; James G Herman; Ross C Donehower; Michael A Carducci
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.